Free tool
FAERS Monitor: Phospholine Iodide
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011963 or its brand name (Phospholine Iodide, Echothiophate Iodide). Reports on generic versions are filed under their own applications.
Reports
147
Serious
75
51% of reports
Hospitalization
6
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- intraocular pressure increased27
- drug ineffective22
- visual impairment17
- eye pain13
- visual acuity reduced10
- blindness9
- blindness unilateral8
- ocular hyperaemia8
- eye disorder7
- eye irritation7
- vision blurred7
- glaucoma6
- headache6
- product quality issue6
- malaise5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2007 | 5 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 9 |
| 2011 | 9 |
| 2012 | 9 |
| 2013 | 11 |
| 2014 | 20 |
| 2015 | 9 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 4 |
| 2019 | 8 |
| 2020 | 25 |
| 2021 | 10 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,012 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 27 | 302.9 | 215.3 | 7,814 |
| blindness unilateralSignal | 8 | 81.2 | 41.4 | 556 |
| glaucomaSignal | 6 | 44.6 | 20.4 | 214 |
| visual acuity reducedSignal | 10 | 43.1 | 23.7 | 371 |
| eye painSignal | 13 | 33.0 | 19.6 | 373 |
| blindnessSignal | 9 | 31.6 | 16.8 | 237 |
| eye disorderSignal | 7 | 30.5 | 14.8 | 171 |
| ocular hyperaemiaSignal | 8 | 24.1 | 12.3 | 155 |
| visual impairmentSignal | 17 | 19.6 | 12.6 | 284 |
| eye irritationSignal | 7 | 17.4 | 8.4 | 93 |
| vision blurredSignal | 7 | 7.3 | 3.5 | 32 |
| product quality issueSignal | 6 | 6.3 | 2.9 | 22 |
| drug ineffectiveSignal | 22 | 2.4 | 1.6 | 17 |
| malaise | 5 | 1.6 | 0.7 | 1 |
| headache | 6 | 1.4 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.